GLSI Greenwich LifeSciences Inc

$GLSI My estimate: we’re likely around 700-800 patients currently randomized in the blinded arm, with roughly 60-65 new patient-years being added each month at the current pace. At a blended event rate (mixing the ~4%/year placebo arm and the much lower GP2 arm), that works out to approximately 1.5 new recurrence events per month — putting us somewhere in the 16-20 events range right now. If that trajectory holds, my expectation is a Q1-Q2 2027 interim analysis, hopefully landing around a 22-6 split (placebo-GP2). I believe 22-6 would be strong enough to trigger an early stop for efficacy — though worth flagging that under a standard O’Brien-Fleming boundary at the 28-event look, 22-6 (~HR 0.27, p≈0.0025) sits right at the edge of what’s typically required, not comfortably above it. A slightly wider split (e.g., 23-5 or better) would make an early stop much more likely.”

$GLSI its the San Antonio Breast Cancer conference in December 2026. Snehal likes to release data around that time. i believe this move in related to re-pricing of that and a significantly improving technical picture. i believe the stock will re-test $70 and on positive ph 3 results could easily go to $200. herceptin revenue is 6 billion. if you give a modest 4 multiple that gives you a $1600 stock. assuming significant dilution, beyond what is projected, and you get a $800 stock.

$GLSI One peptide phase 2’s often show encouraging biomarkers, but when they advance to phase 3, they have never shown any statistically significant OS improvement. That’s why I’m not buying GLSI. Of course it can succeed, but I’m not willing to take the risk. $SLS has 4 peptides activating both CD4 and CD8 and epitope spreading. It will succeed. Already has. Buy Sellas instead.

$GLSI Calling for tomorrow being open label update day. Could be wrong but fun to guess.

$GLSI GLSI’s FLAMINGO-01 Phase 3 trial is a standout example of clinical trial efficiency. With 170 to 200 sites worldwide, the company is running a large-scale cancer immunotherapy study at a fraction of typical costs. By leveraging established academic networks like GEICAM, Unicancer, and GBG, GLSI taps into pre-existing infrastructure and staff, avoiding the need to build everything from scratch. This model, combined with internalized operations & a lean structure, has resulted in an annual burn rate of just $7 to $10 million. The recent FDA approval for commercial GP2 lots in the trial further validates the program’s progress. For investors, this efficiency could be a significant advantage as the study advances. Unprecedented for a small-cap biotech, GLSI’s approach largely mirrors AND surpasses the operational scale and cost discipline typically seen in large biopharma trials. ONE of the very few Pharma CEOs & c-suites worthy of their jobs. Or investors’ trust.

$GLSI $RARE Rare is trending #1 on approval. I don’t own it, but kinda disheartening for those shareholders. Our interim data soon. If it’s positive I would be shocked if we don’t gain 500% to 3,000% that day. It gained 3,500 on Phase 2. Very low float. Tight as c-suite shares locked. Shorts already shorted most if the shares…so that will help this rocked. And the Insider Buying in one for the record books. Take a look: Not one single sell. 👇👇👇

$GLSI I'm not too concerned with the volume right now. Heading into the holiday weekend, I would call this a ceasefire. Longs are a little gun shy from the short attacks over the past month or so. Shorts have to know that big news is very likely right around the corner in the lead up to Bio Europe in November. Everybody kind of waiting it out right now. Hoping to see Snehal start throwing some haymakers over the next week or two after Labor Day. Hope everyone has a good holiday weekend.

$GLSI No reason to expect PR tomorrow or Friday with it being holiday weekend, but any time after Monday is game on. I'm still thinking the week of 9/14 for open label update (possibly next week, possibly week of 9/21). Snehal chose to highlight Bio Europe as a major event. I would be shocked if he did not share some open label updates and other derisking events along the way.

$GLSI we only have 2-3 shorts in here talking sh!t , when it goes up , where are you? And this is nothing . I’m not selling until at least $150 a share.

$GLSI If FLAMINGO-01 reaches the 28-event interim with something like 22 placebo recurrences vs 6 GP2, that’s roughly a 73% relative reduction in events. A 23–5 or 24–4 split would be even more compelling and could make an efficacy stop a very realistic possibility

$GLSI What happened?.... O yeah, nothing. Lol. This is just what they do with this stock. I cant wait until the day I wake up one morning, read my Greenwich email, say to myself, O SHIT, then open my brokerage account and say, damn thats a lot of money.....😂 I have a feeling it will be just like that too, I really do. I dont know when, but I personally have yet to find a stock with more potential then this one. If Snehal pulls it off, and I truly believe that he will, there will be many millionaires made. 15k shares strong, go longs💪

$GLSI we are many months or longer away from true goal. Current ridiculously low price should move higher as we get inevitably closer

$GLSI Can’t wait for open arm data in 0-2 weeks. 17 march was the 6-month update. Thursday 17 September is exact 6 months. I guess we will get an update in that week.

$GLSI no worries at all- as I’ve said before this stock is binary either she’s got it or she doesn’t, but I believe she’s got it! So just sit back on these days and perhaps add a few- it’s a low floater and veterans already know how this rolls- I believe we’re in good hands- 😎

$GLSI Yeah a rough day —but as starter and building my position it was a good occasion to add . She 'll be fine.

$GLSI I'm hoping for a little something in my email to explain this. Thank God I have a strong heart! It's getting exciting in here again.

$GLSI GLSI-100 (GP2 + GM-CSF), rests on exceptional historical data. Unprecedented Phase 2b Efficacy Data. Phase 3 studies: Very Low Recurrence Immaculate Safety Profile. Expansion of the Addressable Market. Increased Power: The trial design allows for expansion up to 2,000 patients if necessary to maintain statistical dominance. Interim Analysis Flexibility. Proven Immunogenicity. Immaculate Safety Profile. Immunotherapies and cancer vaccines often face hurdles due to severe toxicities. Highly Optimized & De-Risked Study Design following feedback from the FDA and European Medicines Agency (EMA), GLSI modified its Phase 3 protocol to significantly boost the probability of success. Interim Analysis Flexibility: The study is built to allow the company to file a Biologics License Application (BLA) following the first interim analysis, the second interim analysis, or at the final trial conclusion.

$GLSI my message to all shorts is to cover here while you can. A cover under $20 is a massive W. Or you may be covering at $100 plus if you still have an account left by then. Dont say we didnt warn you.

$GLSI Stock ridiculously underpriced so not believing this run-up is noise. I always say don't wait on data when execs hold huge amount of shares and continue buying as Snehal has

$GLSI having a mgmt and CEO like Snehal makes a big difference to stock price. big insider ownership, he’s continued to buy and he comes across as caring about shareholders significantly as a result.